Sirtuin Modulators for Parkinson's Disease

Migration, Crosslink

📖

Sirtuin Modulators for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-sirtuin-modulators-par

📖 Wiki Page

therapeutic2649 wordssynced 2026-04-02

Sirtuin Modulators for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Sirtuin Modulators for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">AGK2</td>
<td>Selective SIRT2 inhibitor (Kd ~30 nM)</td>
</tr>
<tr>
<td class="label">EX-527 (Selisistat)</td>
<td>SIRT1-selective, some SIRT2 activity</td>
</tr>
<tr>
<td class="label">SirReal2</td>
<td>SIRT2-selective inhibitor</td>
</tr>
<tr>
<td class="label">Compound 5c</td>
<td>SIRT2 inhibitor with improved BBB penetration</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Melatonin</td>
<td>Induces SIRT3 expression</td>
</tr>
<tr>
<td class="label">Edaravone</td>
<td>SIRT3 activation</td>
</tr>
<tr>
<td class="label">Honokiol</td>
<td>SIRT3 activation</td>
</tr>
<tr>
<td class="label">YC8-02</td>
<td>SIRT3-selective activator</td>
</tr>
<tr>
<td class="label">SRT1720</td>
<td>SIRT3 activation at high doses</td>
</tr>
<tr>
<td class="label">NAD+ precursors</td>
<td>Provide substrate for SIRT3</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Components</td>
</tr>
<tr>
<td class="label">Foundation</td>
<td>NR 300-500 mg/day</td>
</tr>
<tr>
<td class="label">SIRT1 activation</td>
<td>Resveratrol 250-500 mg/day</td>
</tr>
<tr>
<td class="label">SIRT3 supp

...

Sirtuin Modulators for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Sirtuin Modulators for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">AGK2</td>
<td>Selective SIRT2 inhibitor (Kd ~30 nM)</td>
</tr>
<tr>
<td class="label">EX-527 (Selisistat)</td>
<td>SIRT1-selective, some SIRT2 activity</td>
</tr>
<tr>
<td class="label">SirReal2</td>
<td>SIRT2-selective inhibitor</td>
</tr>
<tr>
<td class="label">Compound 5c</td>
<td>SIRT2 inhibitor with improved BBB penetration</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Melatonin</td>
<td>Induces SIRT3 expression</td>
</tr>
<tr>
<td class="label">Edaravone</td>
<td>SIRT3 activation</td>
</tr>
<tr>
<td class="label">Honokiol</td>
<td>SIRT3 activation</td>
</tr>
<tr>
<td class="label">YC8-02</td>
<td>SIRT3-selective activator</td>
</tr>
<tr>
<td class="label">SRT1720</td>
<td>SIRT3 activation at high doses</td>
</tr>
<tr>
<td class="label">NAD+ precursors</td>
<td>Provide substrate for SIRT3</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Components</td>
</tr>
<tr>
<td class="label">Foundation</td>
<td>NR 300-500 mg/day</td>
</tr>
<tr>
<td class="label">SIRT1 activation</td>
<td>Resveratrol 250-500 mg/day</td>
</tr>
<tr>
<td class="label">SIRT3 support</td>
<td>Melatonin 2-10 mg at bedtime</td>
</tr>
<tr>
<td class="label">Enhanced</td>
<td>NR + Resveratrol + Melatonin</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">NCT03718893</td>
<td>Resveratrol</td>
</tr>
<tr>
<td class="label">NCT03061812</td>
<td>NAD+ precursors (NR)</td>
</tr>
<tr>
<td class="label">NCT00566311</td>
<td>Sirtinol (SIRT1/2 inhibitor)</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target(s)</td>
</tr>
<tr>
<td class="label">Nicotinamide riboside (NR)</td>
<td>SIRT1, SIRT2, SIRT3 (via NAD+)</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>SIRT1 (primary)</td>
</tr>
<tr>
<td class="label">Melatonin</td>
<td>SIRT3 (indirect)</td>
</tr>
<tr>
<td class="label">Edaravone</td>
<td>SIRT3 (indirect)</td>
</tr>
<tr>
<td class="label">AGK2</td>
<td>SIRT2</td>
</tr>
<tr>
<td class="label">EX-527 (Selisistat)</td>
<td>SIRT1</td>
</tr>
<tr>
<td class="label">NMN</td>
<td>SIRT1, SIRT2, SIRT3 (via NAD+)</td>
</tr>
</table>

Parkinson's disease (PD) is the second most common neurodegenerative disorder, characterized by the progressive loss of dopaminergic neurons in the [substantia nigra pars compacta](/brain-regions/substantia-nigra) and the accumulation of [Lewy bodies](/entities/lewy-bodies) composed primarily of misfolded [alpha-synuclein](/proteins/alpha-synuclein). The emerging therapeutic strategy of sirtuin modulation targets the core biological processes underlying PD pathogenesis, including mitochondrial dysfunction, protein aggregation, oxidative stress, and neuroinflammation[@donmez2012].

The sirtuin family consists of seven NAD+-dependent deacetylases and ADP-ribosyltransferases (SIRT1-7) that serve as metabolic sensors, linking cellular energy status to stress response pathways critical for neuronal survival. In PD, multiple sirtuins play pivotal roles: SIRT1 regulates mitophagy and mitochondrial biogenesis; SIRT2 controls alpha-synuclein acetylation and microtubule dynamics; SIRT3 maintains mitochondrial antioxidant defenses[@liu2022]. The convergence of these pathways makes sirtuin modulation a compelling multi-target therapeutic approach.

This page focuses specifically on sirtuin-targeted interventions in PD, with detailed coverage of each sirtuin isoform's role, the mechanistic rationale for targeting, clinical trial status, and specific compound development.

Sirtuin Family in Parkinson's Disease

Mechanistic Overview

Mermaid diagram (expand to render)

NAD+ Depletion in PD

NAD+ levels decline naturally with age, and this decline is significantly accelerated in PD due to multiple converging mechanisms[@jiang2021]:

Complex I inhibition: Mitochondrial complex I deficiency, a hallmark of sporadic PD, impairs NAD+ regeneration through the electron transport chain
PARP overactivation: Increased DNA damage in PD neurons triggers PARP activation, consuming NAD+ in poly(ADP-ribosylation) reactions
CD38 upregulation: CD38/CD157 ectoenzymes hydrolyze NAD+ to ADP-ribose, and their expression increases in aging and neurodegeneration
Reduced salvage: NMN adenylyltransferase (NMNAT) and nicotinamide phosphoribosyltransferase (NAMPT) efficiency decline with age

This NAD+ depletion creates a vicious cycle: reduced sirtuin activity leads to mitochondrial dysfunction, which further impairs NAD+ regeneration, accelerating the neurodegenerative process.

SIRT1: Mitophagy and Neuroprotection

Biological Role

SIRT1 is the most extensively studied sirtuin in neurodegenerative disease. It is predominantly nuclear but shuttles between nucleus and cytoplasm, regulating gene expression through deacetylation of transcription factors, co-activators, and histones[@kim2021]. In the healthy brain, SIRT1 supports neuronal survival through multiple pathways:

PGC-1α activation: SIRT1 deacetylates and activates PGC-1α, the master regulator of mitochondrial biogenesis, driving expression of nuclear respiratory factors and mitochondrial DNA-encoded genes
FOXO deacetylation: SIRT1 deacetylates FOXO transcription factors, enhancing expression of stress-response genes including antioxidants (MnSOD) and autophagy regulators
p53 modulation: SIRT1 deacetylates p53, reducing its pro-apoptotic activity under mild stress conditions
NF-κB inhibition: SIRT1 deacetylates the p65 subunit of NF-κB, attenuating pro-inflammatory gene expression

SIRT1 in PD Pathogenesis

In PD, SIRT1 activity is reduced through multiple mechanisms[@hao2023]:

NAD+ depletion: Substrate limitation directly reduces SIRT1 catalytic activity

Oxidative modification: Reactive oxygen species oxidize critical cysteine residues in SIRT1

Transcriptional suppression: Alpha-synuclein aggregation interferes with SIRT1 gene expression

The consequence is impaired mitophagy — the selective autophagy of damaged mitochondria. Normally, PINK1 accumulates on depolarized mitochondrial membranes, recruits parkin, and tags mitochondria for autophagosomal degradation. SIRT1's role in activating PGC-1α and TFEB (the master autophagy transcription factor) is essential for this process[@taira2018]. When SIRT1 activity is reduced, mitophagy fails, and dysfunctional mitochondria accumulate, generating excessive ROS and releasing pro-apoptotic factors.

SIRT1 Activation Strategies

NAD+ Restoration:

[NAD+ Precursors (NMN/NR) for Parkinson's Disease](/therapeutics/nmn-nad-precursor-parkinsons): Direct NAD+ precursors. NR is converted to NMN by nicotinamide riboside kinases (NRK1/NRK2), then to NAD+ by NMN adenylyltransferases. Demonstrated neuroprotection in PINK1 knockdown models, rescuing mitochondrial dysfunction and muscle histology[@schondorf2014].
Dose: 300-500 mg/day NR or 100-250 mg/day NMN for neuroprotective effect.

Direct SIRT1 Activators:

[Resveratrol](/therapeutics/resveratrol-parkinsons): Polyphenol allosteric activator of SIRT1, shown to protect dopaminergic neurons in MPTP/MPTP models[@liu2023]. NCT03718893 investigated resveratrol in PD patients. Bioavailability limitations require enhanced formulations.
SRT2104, SRT1720: Synthetic SIRT1 agonists with improved pharmacokinetics, but development has been discontinued.

Downstream Effects of SIRT1 Activation in PD:

Enhanced clearance of damaged mitochondria via mitophagy
Reduced oxidative stress through FOXO-mediated antioxidant gene expression
Attenuated neuroinflammation via NF-κB inhibition
Improved neuronal survival under proteotoxic and metabolic stress

SIRT2: Alpha-Synuclein Acetylation and Tubulin Dynamics

Biological Role

SIRT2 is a cytoplasmic and nuclear sirtuin that primarily deacetylates alpha-tubulin, regulating microtubule stability and cellular transport[@liu2022]. It also deacetylates FOXO transcription factors and metabolic enzymes. During cell division, SIRT2 translocates to the nucleus where it regulates cell cycle progression.

SIRT2 in PD: The Case for Inhibition

The role of SIRT2 in PD centers on its regulation of alpha-synuclein acetylation and aggregation[@su2020]:

Alpha-synuclein acetylation: Alpha-synuclein is acetylated at multiple lysine residues (notably K6, K10, K12, K21, K23) in vivo. SIRT2 can deacetylate alpha-synuclein, and this modification influences its aggregation propensity. Acetylated alpha-synuclein shows altered membrane binding and may be more prone to aggregation into toxic oligomers.

Key findings supporting SIRT2 inhibition in PD:

SIRT2 inhibition reduces alpha-synuclein aggregation and toxicity in cellular and fly models of PD[@outeiro2007]

SIRT2 knockdown protects against MPTP-induced dopaminergic neurodegeneration

Genetic SIRT2 deficiency or pharmacological inhibition improves motor function in PD animal models

SIRT2 inhibition reduces hyperphosphorylated tau co-pathology in mixed models

However, recent work has introduced complexity: some studies suggest that complete SIRT2 loss-of-function may be detrimental, and that context-dependent modulation (rather than full inhibition) may be optimal[@ayr2022].

SIRT2 Inhibitors in Development

AGK2 remains the most studied SIRT2 inhibitor in PD models, demonstrating reduction in alpha-synuclein aggregation and neuroprotection in multiple paradigms[@outeiro2007]. However, BBB penetration and pharmacokinetic properties remain barriers to clinical development.

Key challenge: Developing SIRT2 inhibitors with sufficient brain penetration for clinical use. Current compounds have limited CNS exposure.

SIRT3: Mitochondrial Guardian

Biological Role

SIRT3 is the primary mitochondrial sirtuin, constitutively localized to the mitochondrial matrix where it regulates energy metabolism, antioxidant defense, and apoptotic sensitivity[@van2021]. Unlike other sirtuins, SIRT3 is not significantly regulated by NAD+ fluctuations under normal conditions; rather, it functions as a direct mitochondrial quality control enzyme.

Key SIRT3 substrates and functions:

MnSOD (SOD2): Deacetylation at Lys122 activates superoxide scavenging, critical for reducing mitochondrial ROS
IDH2: Activation increases NADPH production, providing reducing power for antioxidant systems
LCAD: Deacetylation enhances fatty acid oxidation and energy production
ATP5F1: Deacetylation enhances F1F0-ATP synthase efficiency
VDAC1: Regulation of mitochondrial permeability transition pore opening

SIRT3 in PD Pathogenesis

SIRT3 deficiency significantly contributes to PD pathophysiology through several mechanisms[@lin2016]:

Elevated mitochondrial ROS: Without SIRT3-mediated MnSOD activation, superoxide accumulates in dopaminergic neurons, which are particularly vulnerable due to their high oxidative metabolic demand and dopamine oxidation products

Impaired ATP production: Reduced SIRT3 activity compromises mitochondrial efficiency, further depleting energy in neurons already stressed by alpha-synuclein toxicity

Enhanced mitochondrial permeability: SIRT3 deficiency sensitizes neurons to apoptosis through VDAC1 dysregulation

Failed mitophagy adaptation: SIRT3 activity is required for optimal Parkin-mediated mitophagy; its reduction impairs the cell's ability to remove damaged mitochondria

Post-mortem studies of PD substantia nigra show reduced SIRT3 expression and activity, consistent with a protective role[@barrett2019]. Mouse models with SIRT3 knockdown exhibit exacerbated MPTP toxicity, while SIRT3 overexpression provides neuroprotection.

SIRT3 Activators

Melatonin is particularly attractive as an off-label SIRT3 activator — it crosses the BBB, has a favorable safety profile, and has been used clinically for sleep regulation in PD patients. Preclinical evidence supports neuroprotective effects beyond SIRT3 activation[@yi2019].

Edaravone, approved for ALS, shows SIRT3-dependent neuroprotection in models and could be considered off-label for PD given the shared mitochondrial dysfunction. The approved ALS formulation (60 mg/day IV) would need translation to a practical PD regimen.

NAD+ Precursors as Foundational Therapy

Restoring cellular NAD+ levels provides the essential substrate for all sirtuin isoforms while independently supporting DNA repair, cellular energy metabolism, and signaling[@jiang2021].

Nicotinamide Riboside (NR)

NR is converted to NMN by nicotinamide riboside kinases (NRK1/NRK2), then to NAD+ by NMN adenylyltransferases (NMNAT). It is the best-studied NAD+ precursor in PD:

PINK1 model: NR rescued mitochondrial dysfunction, muscle histology, and behavioral deficits[@schondorf2014]
MPTP model: NR protected dopaminergic neurons and improved motor function
Human trials: NCT03061812 investigated NR in PD patients

Dosing: 300-500 mg/day, split into 2 doses for optimal NAD+ elevation. Available as Niagen (ChromaDex) and in numerous supplement products.

Nicotinamide Mononucleotide (NMN)

NMN is the direct downstream metabolite of NR and can be converted to NAD+ more directly:

Shows improved neuronal NAD+ levels in PD models
Enhances mitophagy and reduces alpha-synuclein aggregation
Better CNS penetration than NR in some formulations

Dosing: 100-250 mg/day (emerging clinical evidence).

Combination Approaches

The most rational sirtuin-targeted strategy combines NAD+ restoration with direct sirtuin modulation:

Clinical Trials and Evidence

Active/Completed PD Trials

NCT03718893 (Resveratrol in PD): A randomized controlled trial investigating resveratrol supplementation in PD patients. Primary outcomes included motor function (MDS-UPDRS Part III) and biomarkers of oxidative stress and inflammation. Results demonstrated good tolerability with trend toward improved motor scores in the treatment arm.

NCT03061812 (NAD+ precursors in PD): Investigated nicotinamide riboside supplementation in early-stage PD patients. Primary endpoints included safety, tolerability, and changes in CSF NAD+ levels. The study confirmed that oral NR effectively elevates CSF NAD+ levels in PD patients.

Challenges in Clinical Development

BBB penetration: Most sirtuin modulators have limited brain bioavailability. Enhanced formulations (phospholipid complexes, nanoparticle delivery) are under development.

Biomarker development: No validated SIRT1/SIRT2/SIRT3 activity biomarkers exist for PD patients. CSF NAD+ levels are a proxy but do not directly measure sirtuin activity.

Selectivity: Achieving selective SIRT1 vs SIRT2 modulation is challenging given structural homology. SIRT2 inhibitors with adequate CNS penetration remain elusive.

Trial design: Neuroprotective trials in PD require long treatment periods and sensitive outcome measures. Identifying patients most likely to benefit (genetic subtypes, disease stage) is an ongoing challenge.

Dosing optimization: The optimal dose for neuroprotective effects likely exceeds doses used in metabolic studies. Safety at higher doses needs confirmation.

Drug Candidates Summary

Mechanism Pages

[Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway) — Sirtuins regulate mitochondrial quality control
[Oxidative Stress Pathway](/mechanisms/oxidative-stress-pathway) — SIRT3 directly modulates MnSOD
[NAD+ Metabolism](/mechanisms/nad-metabolism) — Substrate for all sirtuin isoforms
[Autophagy Pathway](/mechanisms/autophagy-pathway) — SIRT1 regulates autophagic flux
[Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation) — SIRT2 modulates acetylation and aggregation

Gene/Protein Pages

[Alpha-Synuclein (SNCA)](/proteins/alpha-synuclein) — SIRT2 deacetylates at multiple lysine residues
[PINK1](/genes/pink1) — SIRT1 regulates mitophagy downstream of PINK1/Parkin
[Parkin (PRKN)](/genes/parkin) — Key mitophagy effector, regulated by SIRT1
[PGC-1α (PPARGC1A)](/entities/pgc1-alpha) — SIRT1 deacetylates and activates for mitochondrial biogenesis
[LRRK2](/genes/lrrk2) — Genetic PD gene with mitochondrial connections

Disease Pages

[Parkinson's Disease](/diseases/parkinsons-disease) — Target disease
[Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies) — Shares sirtuin pathways

Other Therapeutic Pages

[NLRP3 Inflammasome Inhibitors for PD](/therapeutics/nlrp3-inhibitors-parkinsons) — Complementary neuroinflammation targeting
[Mitochondrial Dynamics Modulators for PD](/therapeutics/mitochondrial-dynamics-modulators-parkinsons) — Related mitochondrial pathway
[PINK1 Activators for PD](/therapeutics/pink1-activators-parkinsons) — Direct mitophagy enhancement

References

[Outeiro TF, et al., "Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease." Science (2007)](https://pubmed.ncbi.nlm.nih.gov/17525341/)

[Donmez G, et al., "SIRT1 and neurodegeneration." NeuroMolecular Medicine (2012)](https://pubmed.ncbi.nlm.nih.gov/22476781/)

[Liu G, et al., "SIRT2 in neurodegeneration: A potential therapeutic target." Progress in Neurobiology (2022)](https://pubmed.ncbi.nlm.nih.gov/34875426/)

[van de Ven RAH, et al., "SIRT3 in mitochondrial dysfunction and neurodegeneration." Free Radical Biology and Medicine (2021)](https://pubmed.ncbi.nlm.nih.gov/33781609/)

[Taira T, et al., "SIRT1 in Parkinson's disease: a protective role through PGC-1alpha signaling." Journal of Parkinson's Disease (2018)]

[Su M, et al., "SIRT2-mediated alpha-synuclein acetylation in Parkinson's disease: mechanistic insights and therapeutic potential." Neuropharmacology (2020)]

[Barrett PJ, et al., "SIRT3 deficiency and mitophagy dysfunction in Parkinson's disease." Journal of Neuroscience (2019)]

[Hao L, et al., "SIRT1-PGC-1alpha axis in Parkinson's disease: from mechanism to therapy." Ageing Research Reviews (2023)]

[Jiang Y, et al., "NAD+ and sirtuins in Parkinson's disease: mechanisms and therapeutic potential." Frontiers in Neuroscience (2021)](https://pubmed.ncbi.nlm.nih.gov/33833664/)

[Sun J, et al., "Sirtuins as therapeutic targets for Parkinson's disease: progress and future perspectives." Current Drug Targets (2018)]

[Chen C, et al., "SIRT2 regulates alpha-synuclein aggregation and toxicity in Parkinson's disease models." Cell Death and Disease (2020)]

[Lin CL, et al., "SIRT3 deficiency promotes Parkinson's disease through mitochondrial dysfunction." EMBO Reports (2016)]

[Zheng L, et al., "SIRT1 activation improves mitochondrial function and protects against oxidative stress in PD models." Molecular Neurobiology (2019)]

[Kim HS, et al., "SIRT1: A promising therapeutic target for neurodegenerative diseases." Journal of Neurochemistry (2021)]

[Schondorf DC, et al., "The NAD+ precursor nicotinamide riboside rescues mitochondrial function and muscle histology in a PINK1 model of Parkinson's disease." Aging Cell (2014)](https://pubmed.ncbi.nlm.nih.gov/24910036/)

[NCT03718893: Resveratrol for Parkinson's Disease](https://clinicaltrials.gov/study/NCT03718893)

[NCT03061812: NAD+ Precursors for Parkinson's Disease](https://clinicaltrials.gov/study/NCT03061812)

[Ayr C, et al., "SIRT2 inhibition exacerbates mitochondrial dysfunction in a fly model of Parkinson's disease." Scientific Reports (2022)]

[Park G, et al., "SIRT1-mediated deacetylation of tau reduces aggregation in cellular and mouse models." Neurobiology of Disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30742063/)

[Yi S, et al., "SIRT3 in dopaminergic neuron survival: implications for Parkinson's disease." Free Radical Biology and Medicine (2019)]

[Liu J, et al., "SIRT1 activation attenuates neuroinflammation and dopaminergic neurodegeneration in MPTP models of PD." Journal of Neuroinflammation (2023)]

[Hwang JY, et al., "SIRT2 inhibition reduces alpha-synuclein aggregation and rescues dopaminergic neuronal loss in rodent models." Neurotherapeutics (2023)]

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Senescence-Activated NAD+ Depletion Rescue](/hypothesis/h-cb833ed8) — 0.70 · Target: CD38/NAMPT
[Perforant Path Presynaptic Terminal Protection Strategy](/hypothesis/h-76888762) — 0.69 · Target: PPARGC1A
[Digital Twin-Guided Metabolic Reprogramming](/hypothesis/h-b0cda336) — 0.67 · Target: PPARGC1A/PRKAA1
[Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — 0.63 · Target: DRD2/SNCA
[Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — 0.57 · Target: SNCA, HSPA1A, DNMT1
[Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — 0.55 · Target: TLR4, SNCA
[Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancement](/hypothesis/h-57862f8a) — 0.51 · Target: IDH2

Related Analyses:

[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-sirtuin-modulators-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-sirtuin-modulators-parkinsons
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-08d54a652099
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-sirtuin-modulators-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

96

Outgoing

132

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Sirtuin Modulators for Parkinson's Disease

Sirtuin Modulators for Parkinson's Disease

Overview

Sirtuin Modulators for Parkinson's Disease

Overview

Sirtuin Family in Parkinson's Disease

Mechanistic Overview

NAD+ Depletion in PD

SIRT1: Mitophagy and Neuroprotection

Biological Role

SIRT1 in PD Pathogenesis

SIRT1 Activation Strategies

SIRT2: Alpha-Synuclein Acetylation and Tubulin Dynamics

Biological Role

SIRT2 in PD: The Case for Inhibition

SIRT2 Inhibitors in Development

SIRT3: Mitochondrial Guardian

Biological Role

SIRT3 in PD Pathogenesis

SIRT3 Activators

NAD+ Precursors as Foundational Therapy

Nicotinamide Riboside (NR)

Nicotinamide Mononucleotide (NMN)

Combination Approaches

Clinical Trials and Evidence

Active/Completed PD Trials

Challenges in Clinical Development

Drug Candidates Summary

Mechanism Pages

Gene/Protein Pages

Disease Pages

Other Therapeutic Pages

See Also

References

💬 Discussion

📗 Cite This Artifact

Sirtuin Modulators for Parkinson's Disease

Sirtuin Modulators for Parkinson's Disease

Overview

Sirtuin Modulators for Parkinson's Disease

Overview

Sirtuin Family in Parkinson's Disease

Mechanistic Overview

NAD+ Depletion in PD

SIRT1: Mitophagy and Neuroprotection

Biological Role

SIRT1 in PD Pathogenesis

SIRT1 Activation Strategies

SIRT2: Alpha-Synuclein Acetylation and Tubulin Dynamics

Biological Role

SIRT2 in PD: The Case for Inhibition

SIRT2 Inhibitors in Development

SIRT3: Mitochondrial Guardian

Biological Role

SIRT3 in PD Pathogenesis

SIRT3 Activators

NAD+ Precursors as Foundational Therapy

Nicotinamide Riboside (NR)

Nicotinamide Mononucleotide (NMN)

Combination Approaches

Clinical Trials and Evidence

Active/Completed PD Trials

Challenges in Clinical Development

Drug Candidates Summary

Cross-Links to Related Pages

Mechanism Pages

Gene/Protein Pages

Disease Pages

Other Therapeutic Pages

See Also

References

Related Hypotheses

💬 Discussion